Longitudinal Evaluation of Health Plan Cost per Venous Thromboembolism or Bleed Event in Patients With a Prior Venous Thromboembolism Event During Hospitalization

Bullano, Michael F.; Willey, Vincent J.; Hauch, Ole; Wygant, Gail; Spyropoulos, Alex C.; Hoffman, Lauren A.

doi:10.18553/jmcp.2005.11.8.663

Cited by 114 publications

(93 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6,15 Previous studies have reported real-world clinical and economic consequences associated with VTE using statistical methods (e.g., multivariate adjustment and matched design) to reduce the chances of an influential variable (e.g., concomitant disease and baseline resource utilization) confounding the results. [16][17][18][19][20] However, despite recent trends toward outpatient treatment of VTE and new anticoagulants that are in advanced development for the management of VTE, most of the literature reporting on the consequences and costs associated with VTE is based on data preceding the year 2000. A better and more current understanding of the clinical outcomes and costs of VTE is important for health care systems that strive to reduce their costs and will also aid formulary and policy decision makers in appreciating the cost burden associated with VTE complications.…”

Section: Methodsmentioning

confidence: 99%

“…16,41 Additionally, the mean all-cause cost of hospital-documented recurrent VTE was estimated to be $12,326 (DVT: $11,419; PE: $11,014; DVT + PE: $19,237). 17 Spyropoulos and Lin also quantified the annual cost associated with DVT and PE using administrative claims data from February 1998 to June 2004. For a primary diagnosis of DVT and PE, they reported DVT-and PE-related average health care costs during the 12-month follow-up period of $10,804 and $16,644, respectively.…”

Section: Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries

Lefèbvre¹,

Laliberté²,

Nutescu³

et al. 2012

JMCP

View full text Add to dashboard Cite

BACKGROUND: Patients with venous thromboembolism (VTE) are at increased risk of developing recurrent VTE and post-thrombotic syndrome (PTS), a complication of deep vein thrombosis (DVT) characterized by venous reflux and residual venous obstruction that may manifest as chronic pain and swelling. Therefore, formulary/policy decision makers should understand the clinical and economic consequences associated with VTE.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Limitationsmentioning

confidence: 99%

All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries

Lefèbvre¹,

Laliberté²,

Nutescu³

et al. 2012

JMCP

View full text Add to dashboard Cite

show abstract

“…9 The health care and economic burdens of VTE are not only related to diagnosis and treatment of the initial event, but also to VTE recurrence. [10][11][12] Spyropoulos and Lin (2007) reported that hospital readmission rates of hospitalized VTE patients were between 5.3% and 14.3% by 1 year. 10 It is important to better understand the overall health care and economic burdens of recurrent VTE among both inpatient-and outpatienttreated VTE patients and to define populations at high risk for VTE recurrence in order to potentially improve the quality of care for VTE patients.…”

Section: Vte Recurrence Definitionmentioning

confidence: 99%

Incremental Health Care Resource Utilization and Economic Burden of Venous Thromboembolism Recurrence from a U.S. Payer Perspective

Lin¹,

Lingohr-Smith²,

Kwong³

2014

JMCP

View full text Add to dashboard Cite

show abstract

“…These higher costs compared with earlier studies may be ar esult of the data we used, including inpatient as well as outpatient payments to providers. Like Bullano et al 21 we used net payer costs (i.e., after subtraction of member cost), but we used outpatient costs that included pharmacy as well as inpatient hospital costs. We also report the costs associated with as econdaryd iagnosis of DVT or PE, providing an estimate of the relative component that aV TE event has in the total health carec ost of patients presenting with comorbidities.…”

mentioning

confidence: 99%

Direct Medical Costs of Venous Thromboembolism and Subsequent Hospital Readmission Rates: An Administrative Claims Analysis From 30 Managed Care Organizations

Spyropoulos

Lin²

2007

JMCP

Self Cite

293

233

View full text Add to dashboard Cite

JMCP Journal of Managed Care Pharmacy 475V enous thromboembolism (VTE) is ac ommon medical condition comprising deep vein thrombosis (DVT) and pulmonarye mbolism (PE). VTE is of particular importance in the hospital setting since moret han half the cases of VTE areaccounted for by institutionalization, with 24% of the cases attributable to hospitalization for surgery. 1 In the absence of prophylaxis, the incidence of objectively confirmed, hospital-acquired DVT ranges from 10% to 40% in the medical and general surgical population to as high as 40% to 60% in patients who have undergone orthopedic surgery. 2 Furthermore, What is already known about this subject•VTE is acommon medical condition of particular importance in the hospital setting. In patients with major surgery, the diagnosis and treatment of an initial VTE event poses as ignificant economic burden to health careinthe United States.•The diagnosis and treatment of the initial VTE event incurs costs, but the VTE recurrences and long-term complications of VTE create additional costs. It was found previously that 1i n4 patients who experienced aV TE event during the incident hospital stay had additional VTE-related events requiring hospitalization in the 21 months of follow-up. These events incurred an average health plan cost of $14,957 per event, or $2,101 per patient per year. What this study adds•T he total annual health carec ost for aV TE ranged from $7,594 to $16,644, depending on the type of event and whether it was a primaryo rs econdaryd iagnosis. The hospital readmission rates of DVT or PE within 12 months were5 .3% for primarya nd 14.3% for secondarydiagnoses.•T he recurrent DVT event was associated with 21% greater cost compared with the initial DVT event, but therew as no difference in cost for the recurrent PE event compared with the initial PE event.•T he use of health plan total medical costs, including outpatient medical and pharmacy in this study,r esulted in higher total costs compared with previous studies that used hospital inpatient costs.BACKGROUND: Venous thromboembolism (VTE) is acommon medical condition manifested as deep vein thrombosis (DVT) or pulmonaryembolism (PE). Few data exist on the total economic burden of DVT and PE.OBJECTIVE: To (1) quantify the economic burden of DVT and PE in direct medical costs and utilization and (2) determine the rates of hospital readmission for DVT and PE.METHODS: Hospital claims containing DVT or PE as aprimaryorsecondary discharge diagnosis during the period February1998 through June 2004 were identified by retrospective analysis using the Integrated Health CareInformation Services (IHCIS) National Managed CareDatabase.For the cost analysis, we included patients that had been enrolled in ahealth careplan for aminimum of 30 days prior to and 365 days following the DVT or PE hospitalization. For the readmission analysis, patients wererequired to have aminimum length of stay of 3days and apreenrollment of 365 days. We quantified the cost burden to the health plan by examining annual DVT-...

show abstract

Longitudinal Evaluation of Health Plan Cost per Venous Thromboembolism or Bleed Event in Patients With a Prior Venous Thromboembolism Event During Hospitalization

Cited by 114 publications

References 54 publications

All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries

All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries

Incremental Health Care Resource Utilization and Economic Burden of Venous Thromboembolism Recurrence from a U.S. Payer Perspective

Direct Medical Costs of Venous Thromboembolism and Subsequent Hospital Readmission Rates: An Administrative Claims Analysis From 30 Managed Care Organizations

Contact Info

Product

Resources

About